JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
JCR Pharmaceuticals Co., Ltd. reports a significant drop in net sales and profits for FY2024 Q1 compared to the previous year, with net sales decreasing by 24.6% and profits attributable to owners of the parent plunging by 87.5%. The company attributes the fall in sales to a decline in core product sales and announces a gain in extraordinary income from contract cancellations.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
